Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
91. |
ECCT/24/08/03 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Mary Inziani Matilu Site(s) in Kenya 1. KEMRI-Mtwapa Clinical Annex (Kilifi county) 2. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 3. Clinical Research Health Network (CREA-N) (Machakos county) 4. University of Nairobi Clinical Research Centre (Nairobi City county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
21-12-2024 |
View |
92. |
ECCT/24/07/05 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Bernhards Ogutu Site(s) in Kenya 1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county) |
20-08-2024 |
View |
93. |
ECCT/24/08/06 | KALUMA Study A randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥ 5 kg body weight followed by an Extension phase with repeated KLU156 treatment |
Principal Investigator(s) 1. Dr Patricia Odera Ojwang 2. Dr. Bernhards Ogutu 3. Dr.Bernhards Ogutu Site(s) in Kenya 1. Site 1600: Kenya Medical Research Institute/Centre for Global Health Research Siaya (Siaya county) 2. Site 1601:Kombewa Clinical Research Centre (Kisumu county) 3. Ahero Clinical Trial Unit (Kisumu county) |
26-01-2025 |
View |
94. |
ECCT/24/10/05 | Cabotegravir + Rilpivirine Inj A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) |
29-04-2025 |
View |
95. |
ECCT/24/07/02 | TMC278LAHTX4002 A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies |
Principal Investigator(s) 1. Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county) 3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county) 4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county) 5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county) |
16-04-2025 |
View |
96. |
ECCT/24/07/01 | LCCC 2330 Feasibility of intravaginal artesunate as adjuvant HPV & cervical precancer treatment among women living with HIV in Kenya: A Phase II trial |
Principal Investigator(s) 1. Chemtai Mungo Site(s) in Kenya Cervical Cancer Screening Program (CCSP) Lumumba Sub-County Hospital |
25-11-2024 |
View |
97. |
ECCT/24/06/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
28-07-2024 |
View |
98. |
ECCT/24/06/04 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N) (Machakos county) |
23-10-2024 |
View |
99. |
ECCT/24/07/03 | RVF003 Trial Phase 2 trial to assess the immunogenicity and safety of the ChAdOx1 RVF vaccine against Rift Valley fever in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-Wellcome Trust Research Programme |
06-01-2025 |
View |
100. |
ECCT/24/08/04 | WHO A66045 Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Machakos county hospital (Machakos county) 2. Pumwani maternity hospital (Nairobi City county) 3. Kiambu level 5 hospital (Kiambu county) |
06-02-2025 |
View |